Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Achaogen's lead antibiotic succeeds two key studies; shares soar

Achaogen Inc's lead antibiotic was successful in two key studies, spurring the company to proceed with regulatory submissions in the United States and Europe, and shares soared 76 percent to their highest in more than a year and half.

In a late-stage study, CARE, involving patients with serious infections due to carbapenem-resistant enterobacteriaceae (CRE), treatment with the drug, plazomicin, resulted in lower mortality rates or serious complications, compared with colistin therapy, one of the few antibiotics still used to treat CRE.

ChemSpider 2D Image | Plazomicin | C25H48N6O10

CRE is relatively rare, but the U.S. Centers for Disease Control and Prevention has deemed it a "nightmare bacteria" because it spreads easily, is increasingly resistant to existing antibiotics, and can kill up to half of its victims.

Data shows there were about 65,000-75,000 cases of CRE in the United States last year, the company said on a conference call with analysts.

In a separate late-stage trial called EPIC, plazomicin was found to be as effective as the broad spectrum antibiotic, meropenem, in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis, Achaogen said.

Ac UTI is associated with an underlying condition, which increases the risk of failing therapy. Pyelonephritis typically occurs when bacteria migrate from the bladder to the kidney, infecting the organ.

Achaogen said it planned to submit a marketing application, including data from both studies, to the U.S. Food and Drug Administration in the second half of 2017 and the European Medicines Agency in 2018.

The biotech company's shares jumped to $9.25 in morning trading on Monday. Up to Friday's close, Achaogen's stock had fallen 8.54 percent since the start of the year.

William Blair's Katherine Xu has forecast peak plazomicin sales of $270 million for cUTI and $70 million for CRE in 2031, if approved, in a client note published in November.

The plazomicin program is funded in part with an up to $103.8 million contract from the Biomedical Advanced Research and Development Authority, or BARDA, a unit of U.S. Department of Health and Human Services.

Antimicrobial resistant, or superbug, infections, kill hundreds of thousands of people a year and has been described by the World Health Organization as "one of the biggest health challenges of the 21st century."

(Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva and Martina D'Couto)

Mon Dec 12, 2016

Source: http://www.reuters.com/


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies